3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
8
Thoracic
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Thromboembolism
3
Venous Thrombosis
2
Colorectal Neoplasms
2
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Pulmonary Embolism
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Hemorrhage
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
Dalteparin
2
isoquercitrin
1
abelacimab
1
Tinzaparin
1
Nadroparin
1
MAA868
1
Heparin, Low-Molecular-Weight
1
Gemcitabine
1
Fondaparinux
1
ALT-836
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Venous Thromboembolism
×
Tinzaparin
×
Gastrointestinal
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled